FiercePharma21 天
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Hyaluronidase is an enzyme that facilitates subcutaneous absorption of the active drug nivolumab. The subcutaneous version could transform the way care is delivered to patients, as it allows ...
The American Journal of Managed Care21 天
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...
Cure Today27 天
Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors
Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The CHECKMATE-67T trial showed a 24% response rate for subcutaneous Opdivo ...
Targeted Oncology27 天
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
The FDA has approved the subcutaneous formulation of nivolumab (Opdivo). This approval makes it the first and only subcutaneously administered PD-1 inhibitor. Subcutaneous nivolumab is approved in all ...
BioPharma Dive2 个月
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
The drugmaker said it plans to discuss data for the subcutaneous form of its cancer immunotherapy with the FDA and other regulators “as soon as possible.” With Keytruda’s market exclusivity running ...
Frontiers2 年
Subtype-Specific Surface Proteins on Adipose Tissue Macrophages and Their Association to ...
we performed a surface proteome screening of pro- and anti-inflammatory ATMs in both subcutaneous- (SAT) and visceral adipose tissue (VAT) and evaluated their relationship with systemic insulin ...